• Booth: 3654

Fitzgerald is a manufacturer and supplier of primary antibodies, secondary antibodies, recombinant and native proteins, ELISA kits, Serum and Plasma, and many other biological reagents. We pride ourselves in our hands-on approach to customer service and our highly reliable technical support in a broad range of research areas such as infectious disease, neuroscience, cancer, heart disease, immunology, and cell biology to name a few. Fitzgerald Industries has joined the Biosynth Group.

 Press Releases

• Biosynth agrees to acquisition of Fitzgerald Industries International from Trinity Biotech (Jun 02, 2023)

  Deal extends product portfolio to 57,000 antigens and antibodies across global biologics offering

  UPDATE 27-APR-2023- This Deal was Completed: Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth | Nasdaq

  Biosynth, a global supplier of critical materials to the pharma and diagnostics industries, are pleased to announce that they have agreed to acquire Fitzgerald Industries International, a leading provider of biological reagents, from Trinity Biotech.

  Commenting, Dr. Urs Spitz, CEO and President of Biosynth, said, “Biosynth is building a world-class offering of critical biological materials for the diagnostics industry. The combination of Fitzgerald Industries and our acquisition of Dublin-based Aalto Bio Reagents last year extends our product portfolio to 57,000 antigens and antibodies, and brings us truly global scale. The acquisition continues the expansion of our offering across complex chemicals, peptides and key biologics to help secure fragmented pharma and diagnostics supply chains. We are excited to work with the Fitzgerald Industries team to further grow and deliver the best to our customers.”  

  For all valued customers of Fitzgerald Industries International, there will be no operational impact at this time and the business will continue to transact as usual. We are determined to maintain Customer Experience as our top priority during this process, and we will be reaching out with more details related to this transition as they become available.
  
  Biosynth and Fitzgerald Industries aim to deliver more value to their customers by combining their strong customer base and extensive offering of biological reagents, chemicals, and peptides. Biosynth has more than a million products in their catalog as well as custom services across all areas. More than just a future acquisition, by creating the leading collection of antigens and antibodies, Biosynth shows a commitment to growth and the securing of supply chains for our customers critical biological reagents.

  Read Full Press Release here 20230420 Press Release_ Final.pdf (biosynth.com)

• Biosynth Further Strengthens Peptide Business with acquisition of Cambridge Research Biochemicals. (Jun 26, 2023)

  Staad, 09 May 2023 – Biosynth, a supplier of critical raw materials to the life science industry, announces today that it has acquired Cambridge Research Biochemicals (“CRB”), a leading independent producer of custom-made peptide and antibody tools, based in the UK and supplying researchers in the pharmaceutical, life science and academic sectors.  CRB brings a wealth of expertise to Biosynth’s peptide division, which has existing operations in the US and the Netherlands. This includes leading expertise in complex peptide chemistry and fluorescent dye labelling. CRB also brings additional custom antibody capacity in Europe, to support customers through the generation of novel, complex or unusual mono- and poly-clonal antibodies unavailable in catalogs.  Dr. Urs Spitz, CEO and President of Biosynth, said, “CRB has a long history in the peptide and antibody field, and we are excited to welcome their highly skilled team to our growing peptide division. Having a network of peptide sites at key locations, staffed by industry experts, allows us to best serve our customers throughout research and development and with the most complex and labelled peptides and high quality antibodies.”   “We are excited to be joining the Biosynth family”, added Emily Humphrys, Managing Director of Cambridge Research Biochemicals.  “As one of the longest established peptide companies, we have over 40 years of experience and are proud to have a strong track record for peptide and antibody excellence with our customers. We see great similarities in the approach that Biosynth already take in leading with science and customer focus.” 

  About Biosynth Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. 

  About Cambridge Research Biochemicals
  Cambridge Research Biochemicals (www.crbdiscovery.com) is a leading independent producer of custom-made peptide and antibody tools, supplying researchers in the pharmaceutical, life science and academic sectors worldwide. The primary applications of its products are as custom-made, laboratory scale reagents for proof of principal studies within early phase drug discovery and to support biomarker programmes in clinical studies. The company produces all flavours of peptides from simple to modified, stable and radio-labelled to dye labelled from milligrams to gram-scale to the highest levels of purity. In addition, CRB is a recognised expert at generating highly specific and targeted antibodies (both polyclonal and monoclonal). Fluorescent dye labelling is also a focus.
  Media Contacts
  Biosynth
  Aimee Cossins
  +44 7984 525560
  marketing@biosynth.com

• Biosynth will be showcasing their Biologics products (Jun 26, 2023)

  Press Release

  Staad, 23 June 2023  Biosynth will be showcasing their Biologics products at AACC Annual Scientific Meeting & Clinical Lab Expo (AACC) booth #4224 as well as #3654 Fitzgerald Industries (recently acquired by Biosynth). including;

  • IgM Humanized mAbs
  • Protein Replacement Capability with Our Peptides 
  • Bioconjugation of Antibodies and Antigens to Magnetic Beads for CLEIA Platforms 

  Come to our booths to discuss the world’s first Rubella IgM Hybrid Human Monoclonal Antibody BM 1361 product, with our expert staff.

  Biosynth is delighted to offer the world’s first solution to replacing natural human Rubella IgM plasma at AACC 2023 in Anaheim. This Rubella IgM is purified by proprietary methodology from cell culture supernatant, concentrated and supplied as a liquid in IgG depleted and delipidised human serum matrix. All but trace amounts of growth medium animal content have been removed to make this product the most ESG friendly product on the market. The product is confirmed negative for HBsAg, HIV-1, HIV-2 and HCV by FDA approved methods. For more information on this and all of our other new humanized monoclonals.

  Biosynth’s Peptide, and Chemical divisions will also be available to discuss the end-to-end manufacturing process that Biosynth encompasses. From the first idea to the finished product Biosynth is securing life sciences supply chains for all customers to benefit on their upcoming projects.

  Go to www.biosynth.com/biologics or speak with our experts at booth #4224 as well as Fitzgerald’s booth # 3654 (recently acquired by Biosynth).

  About Biosynth

  Biosynth is a supplier of critical materials, securing life science supply chains with global research, manufacturing, and distribution facilities. Supplying the pharmaceutical, life science and diagnostic sectors; where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. With an unrivaled research product portfolio of over a million products and end-to-end manufacturing services, Biosynth’s expertise and capability runs across Complex Chemicals, Peptides and Key Biologics, all from one trusted partner. Headquartered in Staad, Switzerland, Biosynth is owned amongst others by KKR, Ampersand Capital Partners and management. Find out more about Biosynth at www.biosynth.com.

  Media Contact

  Biosynth

  Aimee Cossins

  +44 7984 525560

  marketing@biosynth.com

• Expanded biological products and custom services offer for Life Science customers. (Jun 26, 2023)

  Staad, 02 Aug 2022 - Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today that it has signed an agreement to acquire EUCODIS Bioscience (“EUCODIS”), experts in engineering and developing enzymes for pharma, biotech and applied markets.

  The two companies have worked together on innovation projects in enzyme development for a number of years, with Biosynth already stocking EUCODIS’ catalogue enzymes as part of its broad research product offering. 

  The acquisition will broaden Biosynth’s biological products and custom services offering, with the biocatalysis, enzyme and recombinant protein expertise of EUCODIS complementing the biological materials supplied by Biosynth to the in-vitro diagnostics industry via its Aalto Bio Reagents subsidiary. Biosynth’s expanded Biologics offering will include custom and catalogue enzymes, antibodies, antigens, plasma along with epitope mapping services.

  As part of the Biosynth group, EUCODIS will continue to provide state of the art services with the added benefit that customers will now profit from the combined expertise of EUCODIS and Biosynth in enzymes and chemical syntheses to enable novel biocatalytic synthesis routes for small molecules.

  Dr. Urs Spitz, CEO and President of Biosynth, said, “Biosynth has collaborated with EUCODIS for many years, working on innovative enzyme projects for our customers and perfectly complementing our extensive expertise in enzyme substrate chemistry.  It makes absolute sense for EUCODIS to join us as a key part of our biological materials offering. We are delighted to be able to welcome the experienced and knowledgeable team we know so well into the Biosynth family.” 

  Dr. Jan Modregger, CEO of EUCODIS, added, “We are pleased to be joining Biosynth, a group with which we have enjoyed a longstanding relationship and which shares our science-led and customer focused philosophy. We are excited by the opportunity to grow even faster and to provide high performance enzymes and biocatalysis solutions to a global customer base.”

  About Biosynth Carbosynth

  Biosynth Carbosynth is a supplier of critical materials to the life science industry with global research, manufacturing and distribution facilities. It is the supplier of choice for many in the pharmaceutical and diagnostic sectors and manufactures and sources a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, enzyme substrates, peptides, phospholipids, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Headquartered in Staad, Switzerland, Biosynth Carbosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth Carbosynth at www.biosynth-carbosynth.com.

  About EUCODIS

  EUCODIS Bioscience delivers high-performance enzyme solutions for applications in pharma, biotech, fine chemicals, food & feed, as well as the cosmetics industries. With a portfolio of over 50 enzymes including innovative lipases, beta-lactamases, peroxidases and other enzymes, EUCODIS Bioscience has a proven track record of providing customised solutions. As an application-driven provider of tailored enzyme solutions, the company works closely with its customers to better understand and fulfill their individual biocatalyst needs. Founded in 2007, EUCODIS has its headquarters in Vienna, Austria. For further information please visit www.eucodis.com. 

  Media Contacts

  Biosynth 
  Aimee Cossins
  +44 7984 525560
  marketing@biosynth.com

• Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. (Jun 26, 2023)

  Staad, 25 May 2022 - Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease.

  The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD industry. Aalto’s product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants.

  Dr. Urs Spitz, CEO and President of Biosynth, said, “This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.”

  Philip Noone, CEO of Aalto, added, “We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.”

  Find out more about Biosynth's key biologics.

  About Biosynth Carbosynth

  Biosynth Carbosynth is a supplier of critical materials to the life science industry with global research, manufacturing and distribution facilities. It is the supplier of choice for many in the pharmaceutical and diagnostic sectors and manufactures and sources a vast range of chemical and biochemical products. The company specializes in carbohydrates, nucleosides, enzyme substrates, peptides, phospholipids, antimicrobials, APIs and natural products and has a full range of reagents for protein production and analysis. Headquartered in Staad, Switzerland, Biosynth Carbosynth is owned by KKR, Ampersand Capital Partners and management. Find out more about Biosynth Carbosynth at www.biosynth-carbosynth.com.

  About Aalto Bio Reagents

  Aalto Bio Reagents, founded in 1978, is a leading developer and provider of biological raw materials to the in-vitro diagnostics industry and to research laboratories globally. It serves the largest multinational companies in the industry with a broad range of purified human proteins; monoclonal and polyclonal antibodies; fungal, parasitic, bacterial and viral antigens; and disease state plasma for in-vitro diagnostic application. Headquartered in Dublin, Ireland, the company is rapidly expanding both its product portfolio and customer base. For further information please visit http://www.aaltobioreagents.com

  Media Contacts

  Biosynth Carbosynth

  Aimee Cossins

  +44 7984 525560

  marketing@biosynth.com

 Additional Info